FRO - INTERIM REPORT APRIL - JUNE 2005
August 24, 2005 02:53 ET
|
Frontline plc.
Highlights
Frontline reports net income of $127.5 million and earnings per share of $1.70 for the second quarter of 2005.
Frontline reports record half year results of $407.2...
Odfjell Rapport 2.kvartal 2005
August 24, 2005 02:47 ET
|
Odfjell SE
Rapport for 2. kvartal 2005 vedlagt:...
Odfjell Report 2nd Quarter 2005
August 24, 2005 02:47 ET
|
Odfjell SE
Full second quarter report is enclosed:...
Notification to the Oslo Stock Exchange re purchase of own shares
August 24, 2005 02:39 ET
|
Telenor
Telenor's largest shareholder, the Kingdom of Norway, has committed to participate in the buyback by cancelling a proportionate part of its shares, leaving their ownership unchanged. The compensation...
Melding til Oslo Børs vedr. kjøp av egne aksjer
August 24, 2005 02:37 ET
|
Telenor
Staten har, som Telenors største aksjeeier, forpliktet seg til å delta i tilbakekjøpet ved å kansellere en proporsjonal del av sine aksjer slik at statens eierandel forblir uendret....
RaySearch Laboratories AB Interim Report, January 1 -- June 30, 2005
August 24, 2005 02:08 ET
|
RaySearch Laboratories
STOCKHOLM, Sweden, Aug. 24, 2005 (PRIMEZONE) -- RaySearch Laboratories AB (publ):
- Net sales for the period amounted to SEK 33.7 M (20.5)
- Profit after tax totaled SEK 14.2 M (5.7)
-...
Basilea Pharmaceutica Ltd. Reports its Interim Results
August 24, 2005 01:29 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Aug. 24, 2005 (PRIMEZONE) -- Basilea realizes CHF 95.9 million from Johnson & Johnson under ceftobiprole license agreement in the first half of 2005; cash and short-term...
Basilea Pharmaceutica Ltd. (SWX: BSLN) reports its interim results.
August 24, 2005 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, Switzerland, August 24, 2005
Basilea realizes CHF 95.9 million from Johnson & Johnson under ceftobiprole license agreement in the first half of 2005; cash and short-term...
Basilea Pharmaceutica AG (SWX: BSLN) präsentiert Halbjahreszahlen
August 24, 2005 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, 24. August 2005
Im ersten Halbjahr 2005 realisierte Basilea CHF 95.9 Mio. aus der Ceftobiprol Lizenzvereinbarung mit Johnson & Johnson. Die flüssigen Mittel und kurzfristigen...
Basilea Pharmaceutica AG (SWX: BSLN) präsentiert Halbjahreszahlen
August 24, 2005 01:14 ET
|
Basilea Pharmaceutica AG, Allschwil
Basel, 24. August 2005
Im ersten Halbjahr 2005 realisierte Basilea CHF 95.9 Mio. aus der Ceftobiprol Lizenzvereinbarung mit Johnson & Johnson. Die flüssigen Mittel und kurzfristigen...
- October 14, 2024 18:30 ET MaCalus V. Hogan, MD, MBA, Named Orthopaedic Foot & Ankle Foundation President
- October 14, 2024 17:30 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation